Acumen Pharmaceuticals Inc (ABOS) Stock Price

1.86 ▼ -0.12 (-6.06%)
Open: 2.02 Vol: 166.3K Day's range: 1.86 - 2.02 Dec 05, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
ABOS Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 1.88▼ 1.89▼ 1.89▼ 1.88▼ 1.78▲
MA10 1.89▼ 1.90▼ 1.93▼ 1.85▲ 1.92▼
MA20 1.90▼ 1.94▼ 1.91▼ 1.80▲ 1.66▲
MA50 1.92▼ 1.89▼ 1.89▼ 1.93▼ 1.43▲
MA100 1.89▼ 1.84▲ 1.78▲ 1.66▲ 2.23▼
MA200 1.89▼ 1.81▲ 1.94▼ 1.40▲ 3.65▼
  5 mins 30 mins Hourly Daily Weekly
MACD -0.002▼ -0.011▼ -0.011▼ 0.022▲ 0.013▲
RSI 28.478▼ 37.681▼ 41.940▼ 50.105▲ 55.170▲
STOCH 15.278▼ 20.008     17.340▼ 70.461     47.250    
WILL %R -100.000▼ -100.000▼ -100.000▼ -32.075     -48.000    
CCI -221.858▼ -118.462▼ -131.415▼ 65.976     24.583    
Latest Filters Detected On ABOS
MA $ABOS Price Crossed Below MA(50) Set Alert
MA $ABOS Price Crossed Below MA(26) Set Alert
MA $ABOS Price Crossed Below MA(7) Set Alert
▲ GAP $ABOS Open Gap Up %2 Set Alert
CDL $ABOS Engulfing Candlestick Pattern Detected Set Alert
CDL $ABOS Marubozu Candlestick Pattern Detected Set Alert
Acumen Pharmaceuticals Inc News
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at ...
Tuesday, December 02, 2025 05:13 AM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s ...
Tuesday, November 18, 2025 12:00 AM
NEWTON, Mass., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid ...
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
Monday, November 17, 2025 12:00 AM
NEWTON, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid ...
ABOS historical stock data
date open high low close volume
05/12/25 2.02 2.02 1.86 1.86 166,300
04/12/25 1.93 2.00 1.90 1.98 168,900
03/12/25 1.76 1.94 1.76 1.93 136,200
02/12/25 1.89 1.89 1.75 1.75 127,200
01/12/25 1.88 1.936 1.84 1.90 133,600
28/11/25 1.96 2.02 1.88 1.88 53,265
26/11/25 1.94 2.03 1.911 1.95 158,000
25/11/25 1.71 1.96 1.65 1.94 373,900
24/11/25 1.61 1.73 1.61 1.70 148,800
21/11/25 1.55 1.61 1.53 1.57 82,600
Quote Details
52wk Low:0.855
52wk High:2.46
Vol:166.3K
Avg Vol(3m):4.6M
1Y Chng:+0.54%
1M Chng:-15.84%
Add to Watch List
More Information
Index US Composite
Market Cap. 119.94M